1Per Olsson, 1David Hermann, 2Margareta Hammarlund-Udenaes, 2Mats O Karlsson A Population PK/PD model for the irreversible inhibition of 5alpha-reductase types 1 and 2, and the effects on plasma dihydrotestosterone levels.
|
Rik de Greef1, Helen Kastrissios PhD, Jean-Michel Gries PharmD,PhD, Lewis B. Sheiner, MD, Terrence F. Blaschke MD. The Use Of Compliance Data In The Analysis Of A Clinical Trial Of Antiretroviral Drugs In HIV+ Individuals
|
Namik Taright, France Mentré and Alain Mallet Non-Stationarity Of Kinetic Parameters In Multi-Occasion Designs
|
Jixian Wang Two-Stage Procedures For The Analysis Of Cross-Over Trials Using Pharmacokinetic And Pharmacodynamic Models
|
C. Veyrat-Follet1,2, E. Fuseau1, R. Farinotti1, J.L. Palmer2 Is Ipecac Model a good predictor of concentration-efficacy response to Ondansetron in patients?
|
Stuart Beal, Ph.D Analyzing Odd Type Data Using NONMEM
|
Adrian Dunne Population Analysis of Ordinal Categorical Data.
|
Jon Wakefield, Dave Lunn, Nicky Best, David Spiegelhalter The Bayesian Approach To Categorical Responses
|
Etienne Chatelut, Alan V. Boddy, François Doz Subsequent Developments Of Formulas Designed For Predicting Carboplatin Clearance In Adults And In Children
|
Michael Cole, Herbie Newell, Andrew Pearson, John Matthews, Alan Boddy Population Pharmacokinetics Of Etoposide In Children.
|
J.-L. Steimer, B. Fotteler, R. Gieschke, N. Buss, F. Hoffmann-La Roche Mixed-Effects Modelling Of The Dose-AUC Relationship Of Saquinavir Single Dose In Healthy Subjects
|
David J. Lunn & Leon Aarons The pharmacokinetics of saquinavir: a Markov chain, Monte Carlo population analysis
|
C. Anthony Hunt, Serge Guzy and Daniel L. Weiner A Paradigm For Validating Methodologies To Simulate Clinical Trials Validation Of Pharmacodynamic Predictions
|
Nicky Best, Andrew Thomas, David Lunn, Jon Wakefield and David Spiegelhalter New Developments In The BUGS Software For Bayesian Modelling
|
Gomeni R.(1), Mallet A.(2) and Gomeni C NPML-Fit: A Graphical Nonparametric Population Modelling Program
|
Niclas Jonsson and Mats Karlsson XPose 2.0 - An S-Plus Based Population Model Building Aid For NONMEM
|
Milligan P.1, Karlsson M.2, Nichols D. Experiences With Genotype And Phenotype Information In Mixed Effects Modelling
|
Niclas Jonsson Covariate Model Building In Population Analysis
|
Lutz Harnisch, Willi Weber,Hoechst Marion Roussel The Estimation Of Drug-Drug Interactions In Population Pharmacokinetic Trials
|
K. E. Fattinger and D. Verotta The Estimation Of Drug Input Rate Functions By Nonparametric Subject-Specific Population Deconvolution
|
Pascal Girard Under-Compliance And Population Pharmacokinetics
|
Mats O. Karlsson, E. Niclas Jonsson, Curtis Wiltse and Janet R. Wade Assumption Testing In Population Pharmacokinetic Models
|